Results of the AVADO study showed that adding bevacizumab to docetaxel treatment significantly improved progression-free survival for patients with metastatic breast cancer. The AVADO study confirms that the use of bevacizumab in combination with a taxane, in this case docetaxel, increases the chance of reducing tumour burden and prolongs the time for which disease is controlled. The greater ability to control metastatic breast cancer, particularly in patients with immediately life-threatening disease, is reflected in the significant improvement in one-year survival.